Benzothiepine Dioxide Derivatives Inhibit IBAT for Hyperlipidemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hypolipidemic compounds do not adequately address hyperlipidemia and related metabolic disorders, such as insulin resistance and dyslipidemias, with limitations in efficacy and specificity.
Innovation Solution
Development of 1,4-benzothiepine 1,1-dioxide derivatives substituted with benzyl radicals and their physiologically tolerated salts, which exhibit a hypolipidemic effect by inhibiting the uptake of taurocholic acid into cells, thereby reducing lipid levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current hypolipidemic compounds are used, then lipid levels are reduced to some extent, but efficacy is insufficient and specificity is poor
Solution Approach 1:
The patent applies local quality by introducing specific substituents (benzyl radicals, hydroxyl groups, halogens) at particular positions on the benzothiepine core structure. This creates localized functional regions that enhance both the potency (efficacy) and selectivity (specificity) of the compound for its target, resolving the contradiction between general effectiveness and specific action.
Solution Approach 2:
The patent systematically varies structural parameters including the type of substituent (R1-R6), their positions, and the oxidation state of the sulfur atom. These parameter changes optimize the balance between efficacy and specificity, allowing the compounds to achieve superior hypolipidemic activity while maintaining selectivity for the desired biological target.
2Ease of manufacture
If compound structure is simplified, then ease of manufacture increases, but hypolipidemic effect may be reduced
Solution Approach 1:
The patent segments the molecule into a core benzothiepine 1,1-dioxide structure and separable substituent groups (R1-R6). This segmentation allows the core structure to be synthesized once and reused, while only the peripheral substituents need variation, thereby simplifying overall manufacturing while preserving the hypolipidemic effect through systematic substitution patterns.
Solution Approach 2:
The patent changes physical and chemical parameters of the substituents (such as hydrophobicity, molecular weight, and functional group type) to optimize the balance between synthetic accessibility and biological activity. By adjusting these parameters, the patent achieves compounds that are both easier to manufacture and maintain therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively treat hyperlipidemia and related metabolic disorders by inhibiting human IBAT, demonstrating a significant reduction in lipid levels and improving insulin resistance.
Implementation Method 1
The compounds effectively treat hyperlipidemia and related metabolic disorders by inhibiting human IBAT, demonstrating a significant reduction in lipid levels
Data Source
AI summary
This invention relates to Novel 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof.